Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines

Authors: Zeissig, Mara N., Hewett, Duncan R., Mrozik, Krzysztof M., Panagopoulos, Vasilios, Wallington-Gates, Craig T., Spencer, Andrew, Dold, Sandra M., Engelhardt, Monika, Vandyke, Kate, Zannettino, Andrew C.W.

Source: In Leukemia Research April 2024 139

Circular RNAs drive oncogenic chromosomal translocations within the MLL recombinome in leukemia

Authors: Conn, Vanessa M., Gabryelska, Marta, Toubia, John, Kirk, Kirsty, Gantley, Laura, Powell, Jason A., Cildir, Gökhan, Marri, Shashikanth, Liu, Ryan, Stringer, Brett W., Townley, Scott, Webb, Stuart T., Lin, He, Samaraweera, Saumya E., Bailey, Sheree, Moore, Andrew S., Maybury, Mellissa, Liu, Dawei, Colella, Alex D., Chataway, Timothy, Wallington-Gates, Craig T., Walters, Lucie, Sibbons, Jane, Selth, Luke A., Tergaonkar, Vinay, D’Andrea, Richard J., Pitson, Stuart M., Goodall, Gregory J., Conn, Simon J.

Source: In Cancer Cell 10 July 2023 41(7):1309-1326

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies.

Authors: Mynott, Rachel L., Habib, Ali, Best, Oliver G., Wallington-Gates, Craig T.

Source: International Journal of Molecular Sciences; Apr2023, Vol. 24 Issue 8, p7661, 24p

Subject Terms: BONE marrow cancer, NANOMEDICINE, MULTIPLE myeloma, THERAPEUTICS, CELL death, DRUG toxicity